Collaborative RWE Registry Promises Data Transparency

October 27, 2021

The Real World Evidence (RWE) Registry was formed by the International Society for Pharmacoeconomics and Outcomes (ISPOR), the International Society for Pharmacoepidemiology (ISPE), the National Pharmaceutical Council (NPC), and the Duke-Margolis Center for Health Policy. The registry is intended to promote trust and transparency in study design.

“Real-world evidence studies can be used for hypothesis evaluation of treatment effects including safety (HETE studies). However these studies can also be perceived as less rigorous than clinical trials especially when not preregistered in a public setting such as ClinicalTrials.gov or the EU-PAS register. ISPOR and its partners ISPE, NPC, and Duke Margolis have developed a simplified registration site especially for RWE HETE studies using secondary data.” Read more here.

(Source: ISPOR, 10/21)

Share This Story!